You are here

AVAC's Blog: P-Values

In commemoration of World AIDS Day 2019 and this year’s theme, communities make the difference, AVAC is throwing a blog carnival—a series of blog posts that amplify the voices of young advocates who are doing remarkable work to shape the global HIV/AIDS response.

The 20th International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA 2019) is December 2-7, 2019 in Kigali, Rwanda. Find details below on select events of interest and how to follow the conference. AVAC will be there along with many of our partners participating in sessions both before and during the conference. There are several ways you can link to HIV prevention research and rollout-related events—both in-person and from afar.

AVAC released Now What?, our 2019 annual report on the state of the HIV prevention field. Each year, the AVAC Report frames the most pressing advocacy issues facing the HIV response. At the threshold of 2020, it’s clear that global goals for HIV prevention will miss the mark by a long shot.

Due to last-minute scheduling conflicts, we must postpone Friday’s (Nov 15) webinar—PK, PD and F/TAF: What does an advocate need to know about the pharmacology of safety and efficacy and today’s PrEP drugs. We apologize for the inconvenience but stay tuned for details on its rescheduling!

The FDA’s October approval excluded F/TAF as PrEP “for those who have receptive vaginal sex.” Many voices have expressed outrage that Gilead’s strategy for F/TAF regulatory approval left women by the wayside. Gilead had previously claimed finding a relevant cohort of women would not be feasible. In a webinar taking place on November 13, the FDA’s Jeff Murray presented how an innovative design will enable a relatively smaller trial, and the questions it raises.